Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Clinical Trial ID NCT01292655

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.	Nat Rev Clin Oncol	2015	2.02
2	Targeting notch signaling pathway in cancer: clinical development advances and challenges.	Pharmacol Ther	2013	1.96
3	Emerging targeted agents in metastatic breast cancer.	Nat Rev Clin Oncol	2013	1.59
4	Notching on Cancer's Door: Notch Signaling in Brain Tumors.	Front Oncol	2015	0.95
5	Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer.	Cancer Growth Metastasis	2015	0.90
6	Notch signaling in serous ovarian cancer.	J Ovarian Res	2014	0.87
7	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer.	Breast Cancer Res	2013	0.85
8	Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.	ACS Med Chem Lett	2015	0.80
9	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
10	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad.	Oxid Med Cell Longev	2016	0.78